Inhibikase Therapeutics Files SEC Prospectus To Raise Up To $185M Through Existing ATM Program

On December 19, 2025, Inhibikase Therapeutics, Inc. (the "Company") filed with the Securities and Exchange Commission (the "SEC") a prospectus supplement (the "Prospectus Supplement"), dated December 19, 2025, with respect to the Company's existing "at the market offering" program (the "ATM Program"). Pursuant to the Prospectus Supplement, the Company may offer and sell shares of its common stock having an aggregate offering price of up to $185,000,000, from time to time, through Jefferies LLC as sales agent, pursuant to the Open Market Sale AgreementSM, dated as of June 20, 2025, between the Company and Jefferies LLC (the "Sales Agreement").The Prospectus Supplement was filed pursuant to the registration statement on Form S-3 (File No. 333-288213) previously filed with the SEC on June 20, 2025 and declared effective by the SEC on June 27, 2025.